ArticleCell death discovery2025

Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer.

Ibha Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.